Prometheus appoints Peter Heseltine CMO
This article was originally published in Scrip
Prometheus Laboratories, a speciality pharmaceutical and diagnostic company, has appointed Dr Peter Heseltine senior vice-president and chief medical officer. Dr Heseltine has 35 years' experience in the medical field, having most recently served as vice-president and medical director of global businesses for Beckman Coulter since 2005. Prior to this, he led a team of research scientists at Quest Diagnostics developing esoteric tests for infectious diseases.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.